证券代码：688366 证券简称：昊海生科 公告编号：2025-038 上海昊海生物科技股份有限公司 三、《终止合作协议》的主要内容 视觉、乙方及丙方应促使并确保亨泰光学与甲方共同签署《终止确认函》，确认 《独家经销合同》及《技术授权合约书》于亨泰光学与卡尔蔡司《股份转换契约》 项下股份转换基准日前一日终止。 自愿披露关于签订《终止合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、前次交易的基本情况 司昊海生物科技控股有限公司（"昊海控股"）与亨泰光学股份有限公司（"亨 泰光学"）、上海亨泰视觉科技有限公司（"亨泰视觉"）签署《独家经销合同》 《技术授权合约书》（以下合称"独家经销协议"），约定亨泰光学授予亨泰视 觉高端角膜塑形用硬性透气接触镜产品（OK 镜）"迈儿康 myOK"于中国大陆 地区、期限为 10 年（截至 2030 年 12 月 31 日）的独家经销权，昊海控股作为采 购平台；并持续授予亨泰视觉儿童近视管理及控制的光学镜片"贝视得"于中国 大陆地区的独家经销权。同时，公司全资子公司上海昊海 ...

Core Viewpoint - The announcement details a significant partnership and investment involving昊海生物科技,亨泰光学, and亨泰视觉, which includes exclusive distribution rights and equity acquisition, indicating a strategic move to enhance market presence in the optical lens sector [1][2]. Group 1: Exclusive Distribution Agreement -昊海生物科技's subsidiary,昊海控股, has signed an exclusive distribution agreement with亨泰光学 and亨泰视觉 for high-end orthokeratology contact lenses "迈儿康myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also grants昊海控股 exclusive distribution rights for children's myopia management optical lenses "贝视得" in mainland China [1]. Group 2: Equity Acquisition -昊海发展, another subsidiary of昊海生物科技, has entered into an investment agreement to acquire a 55% stake in亨泰视觉 for RMB 25 million, making亨泰视觉 a controlled subsidiary and included in the consolidated financial statements of the company [1]. - Following a change in control of亨泰光学 due to a proposed acquisition by Carl Zeiss Vision International GmbH,昊海控股 and亨泰光学's major shareholders have signed a termination agreement for the existing cooperation [2]. - As part of the termination agreement,亨泰光学's major shareholders will pay昊海控股 a termination compensation of RMB 80 million [2].

Core Viewpoint - The company has entered into exclusive distribution agreements and investment agreements with Hengtai Optical and Hengtai Vision, which will significantly impact its market position in the high-end contact lens sector in China [1][2]. Group 1: Exclusive Distribution Agreements - The company’s wholly-owned subsidiary, Haohai Biotechnology Holdings, signed an exclusive distribution agreement with Hengtai Optical and Hengtai Vision for the high-end orthokeratology contact lens product "myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also includes the exclusive distribution rights for Hengtai Vision's optical lenses for children's myopia management, named "Beishide," in mainland China [1]. Group 2: Investment Agreement - The company’s subsidiary, Haohai Pharmaceutical Technology Development, has signed an investment agreement to acquire a 55% stake in Hengtai Vision for RMB 25 million, making Hengtai Vision a subsidiary and consolidating it into the company's financial statements [1]. Group 3: Termination of Existing Cooperation - Due to Carl Zeiss Vision International's intention to acquire 100% of Hengtai Optical, the existing cooperation between Haohai Holdings and Hengtai Optical will be terminated, with a compensation payment of RMB 80 million to Haohai Holdings [2]. - Following the termination, Hengtai Vision will transfer 45% of its shares from its minority shareholder to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development [2].

独家经销协议正式终止前，各方仍应当正常履行相关协议;在相关交接工作完成后，各方促使并确保亨 泰视觉少数股东金亨泰(厦门)贸易有限公司("金亨泰(厦门)")与昊海发展签署《股权转让协议》，以亨泰 视觉截至2025年9月30日止账面净资产为依据计算股权转让价格，金亨泰(厦门)将其所持有的亨泰视觉 45%股权全部转让给昊海发展，亨泰视觉将成为昊海发展全资子公司，继续纳入公司合并报表范围。 昊海生科(688366.SH)公告，因卡尔蔡司拟通过股份转换的形式收购亨泰光学100%股份，亨泰光学的控 制权将发生变更。公司子公司昊海控股与亨泰光学现有主要股东及利害关系人签署《终止合作协议》。 各方同意在《终止合作协议》签署后，促使并确保亨泰光学与昊海控股、亨泰视觉共同签署《终止确认 函》，并自亨泰光学与卡尔蔡司《股份转换契约》项下股份转换基准日前一日终止独家经销协议，亨泰 光学主要股东及利害关系人向昊海控股支付终止合作补助金8000万元。 ...

Core Viewpoint - Haohai Biology (688366.SH) announced that Carl Zeiss intends to acquire 100% of Hengtai Optical through a share conversion, resulting in a change of control over Hengtai Optical [1] Group 1: Agreement and Termination - Haohai Holdings and Hengtai Optical's existing major shareholders and stakeholders signed a "Termination Cooperation Agreement" [1] - All parties agreed to ensure that Hengtai Optical, Haohai Holdings, and Hengtai Vision sign a "Termination Confirmation Letter" after the "Termination Cooperation Agreement" is signed [1] - The exclusive distribution agreement will be terminated one day before the share conversion benchmark date between Hengtai Optical and Carl Zeiss, with Hengtai Optical's major shareholders and stakeholders paying a termination compensation of 80 million yuan to Haohai Holdings [1] Group 2: Share Transfer and Future Structure - Before the formal termination of the exclusive distribution agreement, all parties must continue to perform related agreements normally [1] - After the completion of relevant handover work, Hengtai Vision's minority shareholder, Jinhengtai (Xiamen) Trading Co., Ltd., will sign a "Share Transfer Agreement" with Haohai Development [1] - The share transfer price will be calculated based on Hengtai Vision's book net assets as of September 30, 2025, with Jinhengtai (Xiamen) transferring its entire 45% stake in Hengtai Vision to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development and continuing to be included in the company's consolidated financial statements [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司自 願披露關於簽訂<終止合作協議>的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月20日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生； 及本公司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 ...

独家经销协议正式终止前，各方仍应当正常履行相关协议；在相关交接工作完成后，各方促使并确保亨 泰视觉少数股东金亨泰（厦门）贸易有限公司（"金亨泰（厦门）"）与昊海发展签署《股权转让协 议》，以亨泰视觉截至2025年9月30日止账面净资产为依据计算股权转让价格，金亨泰（厦门）将其所 持有的亨泰视觉45%股权全部转让给昊海发展，亨泰视觉将成为昊海发展全资子公司，继续纳入公司合 并报表范围。 格隆汇8月20日丨昊海生科(688366.SH)公布，因Carl Zeiss Vision International GmbH（"卡尔蔡司"）拟通 过股份转换的形式收购亨泰光学100%股份，亨泰光学的控制权将发生变更，进而对原合作带来重大变 化。经友好协商，昊海控股与亨泰光学现有主要股东及利害关系人签署《终止合作协议》。各方同意在 《终止合作协议》签署后，促使并确保亨泰光学与昊海控股、亨泰视觉共同签署《终止确认函》，并自 亨泰光学与卡尔蔡司《股份转换契约》项下股份转换基准日前一日终止独家经销协议，亨泰光学主要股 东及利害关系人向昊海控股支付终止合作补助金人民币8,000万元。 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-038 上海昊海生物科技股份有限公司 自愿披露关于签订《终止合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、前次交易的基本情况 2021 年 3 月 19 日，上海昊海生物科技股份有限公司（"公司"）全资子公 司昊海生物科技控股有限公司（"昊海控股"）与亨泰光学股份有限公司（"亨 泰光学"）、上海亨泰视觉科技有限公司（"亨泰视觉"）签署《独家经销合同》 《技术授权合约书》（以下合称"独家经销协议"），约定亨泰光学授予亨泰视 觉高端角膜塑形用硬性透气接触镜产品（OK 镜）"迈儿康 myOK"于中国大陆 地区、期限为 10 年（截至 2030 年 12 月 31 日）的独家经销权，昊海控股作为采 购平台；并持续授予亨泰视觉儿童近视管理及控制的光学镜片"贝视得"于中国 大陆地区的独家经销权。同时，公司全资子公司上海昊海医药科技发展有限公司 （以下简称"昊海发展"）与亨泰视觉及其股东签订《投资协议》，通过股权转 让以及增资的方式以人民币 2,50 ...

昊海生科公告，因Carl Zeiss Vision International GmbH拟通过股份转换形式收购亨泰光学100%股份，亨 泰光学控制权变更，导致原合作协议重大变化。经友好协商，昊海控股与亨泰光学主要股东签署《终止 合作协议》，亨泰视觉少数股东金亨泰（厦门）贸易有限公司将其持有的亨泰视觉45%股权转让给昊海 发展。此外，亨泰光学主要股东及利害关系人向昊海控股支付终止合作补助金人民币8000万元。该事项 无需提交董事会、股东会审议，公司与协议相对方不存在关联关系。 ...

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]